Drug Profile
Research programme: metabolic disorders therapeutics - Jubilant Biosys/ Sanofi Aventis Deutschland GmbH
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Jubilant Biosys; Sanofi Aventis Deutschland GmbH
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Diabetes-mellitus in India
- 28 Feb 2020 No recent reports of development identified for research development in Obesity in India
- 07 Jan 2016 Jubilant Biosys and Sanofi Aventis Deutschland GmbH agree to develop small molecule inhibitors in India for metabolic disorders